Ligustrazine Inhibits Lung Phosphodiesterase Activity in a Rat Model of Allergic Asthma

Objectives This study sought to examine whether ligustrazine was capable of inhibiting phosphodiesterase (PDE) activity and improving lung function in a rat model of asthma. Methods Rats were initially sensitized using ovalbumin (OVA) and then were challenged daily with aerosolized OVA beginning 14 days later (30 min/day) to generate a rat model of asthma. Changes in airway function following methacholine (MCh) injection were evaluated by monitoring lung resistance (RL) and dynamic lung compliance (Cdyn) values using an AniRes2005 analytic system. In addition, serum IgE was measured via ELISA, while PDE expression was evaluated via qPCR and western blotting. Key Findings. Ligustrazine significantly impaired allergen-induced lung hyperresponsivity and inflammation in this asthma model system. Ligustrazine treatment was also associated with reduced expression of PDEs including PDE4 in the lungs of these rats. Conclusions Ligustrazine suppresses airway inflammation and bronchial hyperresponsivity in this rat model system, and these changes are associated with decreased PDE expression at the protein and mRNA levels.

[1]  D. Spina,et al.  PDE4 inhibitors: current status , 2008, British journal of pharmacology.

[2]  G. Dobos,et al.  The model of western integrative medicine: The role of Chinese medicine , 2011, Chinese journal of integrative medicine.

[3]  Xiu-Min Li,et al.  Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. , 2009, The Journal of allergy and clinical immunology.

[4]  Zhenqi Liu,et al.  Tetramethylpyrazine Ameliorates High Glucose-Induced Endothelial Dysfunction by Increasing Mitochondrial Biogenesis , 2014, PloS one.

[5]  W. Liao,et al.  Effects of Tetramethylpyrazine on Functional Recovery and Neuronal Dendritic Plasticity after Experimental Stroke , 2015, Evidence-based complementary and alternative medicine : eCAM.

[6]  M. A. Hossain,et al.  Effect of Rolipram, a Phosphodiesterase IV Inhibitor, on Allergic Footpad Swelling using Various Adjuvants in Mice , 2005, Scandinavian journal of immunology.

[7]  Hua-Hao Shen,et al.  Acetamide-45 inhibited hyperresponsiveness and airway inflammation in mice partly depending on phosphodiesterase activity suppression , 2008, Acta Pharmacologica Sinica.

[8]  D M Essayan,et al.  Cyclic nucleotide phosphodiesterases. , 2001, The Journal of allergy and clinical immunology.

[9]  A. Ammit,et al.  Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells. , 2015, American journal of respiratory cell and molecular biology.

[10]  K. Yin,et al.  Ligustrazine corrects Th1/Th2 and Treg/Th17 imbalance in a mouse asthma model. , 2014, International immunopharmacology.

[11]  K. Chung,et al.  Phosphodiesterase inhibitors in airways disease , 2006 .

[12]  Q. Xie,et al.  Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. , 2006, European journal of pharmacology.

[13]  J. Barberà,et al.  Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial , 2013, European Respiratory Journal.

[14]  H. Ke,et al.  Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. , 2007, The Biochemical journal.

[15]  C. Sousa,et al.  Sildenafil decreases rat tracheal hyperresponsiveness to carbachol and changes canonical transient receptor potential gene expression after antigen challenge. , 2011, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[16]  William M Brown,et al.  Treating COPD with PDE 4 inhibitors , 2007, International journal of chronic obstructive pulmonary disease.

[17]  Yu-Chiang Hung,et al.  Integrated traditional Chinese medicine for childhood asthma in Taiwan: a Nationwide cohort study , 2014, BMC Complementary and Alternative Medicine.

[18]  M. Bruss,et al.  Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. , 2010, The Journal of allergy and clinical immunology.

[19]  Y. Gho,et al.  Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma , 2010, Experimental & Molecular Medicine.

[20]  K. Fan Chung.  Phosphodiesterase inhibitors in airways disease. , 2006, European journal of pharmacology.

[21]  H. Bisgaard,et al.  Intermittent inhaled corticosteroids in infants with episodic wheezing. , 2006, The New England journal of medicine.

[22]  Vernon M Chinchilli,et al.  Long-term inhaled corticosteroids in preschool children at high risk for asthma. , 2006, The New England journal of medicine.

[23]  J. W. Smith,et al.  Alterations in cyclic adenosine monophosphate metabolism in human bronchial asthma. I. Leukocyte responsiveness to -adrenergic agents. , 1973, The Journal of clinical investigation.

[24]  C. Parker,et al.  Alterations in cyclic AMP metabolism in human bronchial asthma. 3. Leukocyte and lymphocyte responses to steroids. , 1973, The Journal of clinical investigation.

[25]  Reynold A Panettieri,et al.  Asthma , 1894, Annals of Internal Medicine.

[26]  Wei Wu,et al.  Tetramethylpyrazine protects against scopolamine-induced memory impairments in rats by reversing the cAMP/PKA/CREB pathway , 2013, Behavioural Brain Research.

[27]  So Ri Kim,et al.  Overlap Between Asthma and COPD: Where the Two Diseases Converge , 2010, Allergy, asthma & immunology research.

[28]  D. Halpin.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD , 2008, International journal of chronic obstructive pulmonary disease.

[29]  C. Billington,et al.  Novel cAMP signalling paradigms: therapeutic implications for airway disease , 2012, British journal of pharmacology.

[30]  L. Fabbri,et al.  Roflumilast , 2011, Nature Reviews Drug Discovery.

[31]  T. Hasegawa,et al.  Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor. , 2002, Biological & pharmaceutical bulletin.

[32]  W. Seeger,et al.  Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia , 2009, European Respiratory Journal.

[33]  M. Grandoch,et al.  The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function , 2010, British Journal of Pharmacology.

[34]  Xiu-Min Li.  Traditional Chinese herbal remedies for asthma and food allergy. , 2007, The Journal of allergy and clinical immunology.

[35]  Jing-Cheng Dong,et al.  [Experimental study on prevention and treatment of bronchial asthma by compound Chinese herbal monomer recipe]. , 2004, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[36]  I. Adcock,et al.  The role of PDE4 in pulmonary inflammation and goblet cell hyperplasia in allergic rats. , 2006, Biochimica et biophysica acta.

[37]  M. Cazzola,et al.  Are phosphodiesterase 4 inhibitors just more theophylline? , 2006, The Journal of allergy and clinical immunology.

[38]  Wei Jiang,et al.  Exploratory study data for determining the adverse effects of sinomenine plus gabapentin or ligustrazine hydrochloride and the pharmacokinetic insights of sinomenine in plasma and CNS tissue , 2019, Data in brief.

[39]  M. Bai,et al.  Effect and mechanism of ligustrazine on Th1/Th2 cytokines in a rat asthma model. , 2007, The American journal of Chinese medicine.

[40]  Hui Wang,et al.  Effect of ligustrazine injection on levels of interleukin-4 and interferon-γ in patients with bronchial asthma , 2008, Chinese journal of integrative medicine.

[41]  H. Ott,et al.  Glucocorticoid hypersensitivity as a rare but potentially fatal side effect of paediatric asthma treatment: a case report , 2008, Journal of medical case reports.

[42]  J. Chen,et al.  Chuanxiongzine relaxes isolated corpus cavernosum strips and raises intracavernous pressure in rabbits , 2009, International Journal of Impotence Research.

[43]  M. Houslay.  Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.

[44]  Ji-qiang Chen,et al.  Upregulation of phosphodiesterase-4 in the lung of allergic rats. , 2005, American journal of respiratory and critical care medicine.

[45]  Q. Xie,et al.  Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma. , 2006, Life sciences.

[46]  K. Chung,et al.  Effect of (cid:1) 2 -adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A , 2008 .

[47]  P. Barnes.  Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. , 2015, The Journal of allergy and clinical immunology.

[48]  F. Faucz,et al.  Clinical and molecular genetics of the phosphodiesterases (PDEs). , 2014, Endocrine reviews.

[49]  G. Anderson.  Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. , 2006, Clinical reviews in allergy & immunology.

[50]  A. Togias,et al.  Phosphodiesterase V Inhibition Reduces Airway Responsiveness, but Does Not Improve the Beneficial Effect of Deep Inspiration , 2013, Respiration.